# *In silico* evaluation of the role of lisdexamfetamine on attention-deficit/hyperactivity disorder common psychiatric comorbidities: mechanistic insights on binge eating disorder and depression

***Supplementary Figures***

**José Ramón Gutiérrez Casares1٭, Cristina Segú-Vergés2,3, Juncal Sabate Chueca4, Tamara Pozo-Rubio4, Mireia Coma2, Carmen Montoto4**, **Javier Quintero5**

1 Unidad Ambulatoria de Psiquiatría y Salud Mental de la Infancia, Niñez y Adolescencia. Hospital Perpetuo Socorro. Badajoz, Spain

2 Anaxomics Biotech, Barcelona, Spain

3 Research Programme on Biomedical Informatics (GRIB), Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain

4 Medical Department. Takeda Farmacéutica España, Madrid, Spain

5 Servicio de Psiquiatría. Hospital Universitario Infanta Leonor. Universidad Complutense. Madrid, Spain

## Supplementary Figures

|  |  |
| --- | --- |
|  | |
|  |  |
| **Figure A. Detailed predicted mechanism of action of virtual lisdexamfetamine over binge eating disorder in attention-deficit/hyperactivity disorder patients presenting this comorbidity.** Supplementary Table C in the S2 File contains the sources of information found in the scientific literature supporting the predicted mechanisms. | |

|  |
| --- |
| Detected  in  adults |
|  |
| **Figure B. Detailed predicted mechanism of action of virtual lisdexamfetamine over depression in attention-deficit/hyperactivity disorder patients presenting this comorbidity.** Supplementary Table D in the S2 File contains the sources of information found in the scientific literature supporting the predicted mechanisms. |